1
|
Feline APOBEC3s, Barriers to Cross-Species Transmission of FIV? Viruses 2018; 10:v10040186. [PMID: 29642583 PMCID: PMC5923480 DOI: 10.3390/v10040186] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2018] [Revised: 04/06/2018] [Accepted: 04/07/2018] [Indexed: 02/07/2023] Open
Abstract
The replication of lentiviruses highly depends on host cellular factors, which defines their species-specific tropism. Cellular restriction factors that can inhibit lentiviral replication were recently identified. Feline immunodeficiency virus (FIV) was found to be sensitive to several feline cellular restriction factors, such as apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3 (APOBEC3) and tetherin, but FIV evolved to counteract them. Here, we describe the molecular mechanisms by which feline APOBEC3 restriction factors inhibit FIV replication and discuss the molecular interaction of APOBEC3 proteins with the viral antagonizing protein Vif. We speculate that feline APOBEC3 proteins could explain some of the observed FIV cross-species transmissions described in wild Felids.
Collapse
|
2
|
Kaye S, Wang W, Miller C, McLuckie A, Beatty JA, Grant CK, VandeWoude S, Bielefeldt-Ohmann H. Role of Feline Immunodeficiency Virus in Lymphomagenesis--Going Alone or Colluding? ILAR J 2017; 57:24-33. [PMID: 27034392 DOI: 10.1093/ilar/ilv047] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Feline immunodeficiency virus (FIV) is a naturally occurring lentivirus of domestic and nondomestic feline species. Infection in domestic cats leads to immune dysfunction via mechanisms similar to those caused by human immunodeficiency virus (HIV) and, as such, is a valuable natural animal model for acquired immunodeficiency syndrome (AIDS) in humans. An association between FIV and an increased incidence of neoplasia has long been recognized, with frequencies of up to 20% in FIV-positive cats recorded in some studies. This is similar to the rate of neoplasia seen in HIV-positive individuals, and in both species neoplasia typically requires several years to arise. The most frequently reported type of neoplasia associated with FIV infection is lymphoma. Here we review the possible mechanisms involved in FIV lymphomagenesis, including the possible involvement of coinfections, notably those with gamma-herpesviruses.
Collapse
Affiliation(s)
- Sarah Kaye
- Sarah Kaye, BVSc, is a small animal clinician with the Animal Welfare League Qld Inc. in The Gold Coast, Queensland, Australia. Wenqi Wang, BVSc, PhD, is a postdoctoral fellow affiliated with the School of Veterinary Science at University of Queensland at Gatton in Australia. Craig Miller, DVM, is a postdoctoral fellow in the Department of Microbiology, Immunology & Pathology at Colorado State University in FortCollins, Colorado. Alicia McLuckie, BVSc, is a PhD candidate in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia, Julia A. Beatty, BSc, BVetMed, PhD, FANZCVs (feline med), is a professor in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia. Chris K. Grant, PhD, DSc, is founder and CEO of Custom Monoclonals International Corp. in West Sacramento, California. Sue VandeWoude, DVM, MS, DACLAM, is a professor in the Department of Microbiology, Immunology & Pathology at Colorado State University and Associate Dean for Research in the College of Veterinary & Biomedical Sciences at Colorado State University in Fort Collins, Colorado. Helle Bielefeldt-Ohmann, DVM, PhD, is a senior lecturer in the School of Veterinary Science at the University of Queensland at Gatton, an affiliate senior lecturer in the School of Chemistry & Molecular Biosciences at the University of Queensland at St. Lucia, and an investigator at the Australian Infectious Diseases Research Centre at the University of Queensland in St. Lucia, Australia
| | - Wenqi Wang
- Sarah Kaye, BVSc, is a small animal clinician with the Animal Welfare League Qld Inc. in The Gold Coast, Queensland, Australia. Wenqi Wang, BVSc, PhD, is a postdoctoral fellow affiliated with the School of Veterinary Science at University of Queensland at Gatton in Australia. Craig Miller, DVM, is a postdoctoral fellow in the Department of Microbiology, Immunology & Pathology at Colorado State University in FortCollins, Colorado. Alicia McLuckie, BVSc, is a PhD candidate in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia, Julia A. Beatty, BSc, BVetMed, PhD, FANZCVs (feline med), is a professor in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia. Chris K. Grant, PhD, DSc, is founder and CEO of Custom Monoclonals International Corp. in West Sacramento, California. Sue VandeWoude, DVM, MS, DACLAM, is a professor in the Department of Microbiology, Immunology & Pathology at Colorado State University and Associate Dean for Research in the College of Veterinary & Biomedical Sciences at Colorado State University in Fort Collins, Colorado. Helle Bielefeldt-Ohmann, DVM, PhD, is a senior lecturer in the School of Veterinary Science at the University of Queensland at Gatton, an affiliate senior lecturer in the School of Chemistry & Molecular Biosciences at the University of Queensland at St. Lucia, and an investigator at the Australian Infectious Diseases Research Centre at the University of Queensland in St. Lucia, Australia
| | - Craig Miller
- Sarah Kaye, BVSc, is a small animal clinician with the Animal Welfare League Qld Inc. in The Gold Coast, Queensland, Australia. Wenqi Wang, BVSc, PhD, is a postdoctoral fellow affiliated with the School of Veterinary Science at University of Queensland at Gatton in Australia. Craig Miller, DVM, is a postdoctoral fellow in the Department of Microbiology, Immunology & Pathology at Colorado State University in FortCollins, Colorado. Alicia McLuckie, BVSc, is a PhD candidate in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia, Julia A. Beatty, BSc, BVetMed, PhD, FANZCVs (feline med), is a professor in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia. Chris K. Grant, PhD, DSc, is founder and CEO of Custom Monoclonals International Corp. in West Sacramento, California. Sue VandeWoude, DVM, MS, DACLAM, is a professor in the Department of Microbiology, Immunology & Pathology at Colorado State University and Associate Dean for Research in the College of Veterinary & Biomedical Sciences at Colorado State University in Fort Collins, Colorado. Helle Bielefeldt-Ohmann, DVM, PhD, is a senior lecturer in the School of Veterinary Science at the University of Queensland at Gatton, an affiliate senior lecturer in the School of Chemistry & Molecular Biosciences at the University of Queensland at St. Lucia, and an investigator at the Australian Infectious Diseases Research Centre at the University of Queensland in St. Lucia, Australia
| | - Alicia McLuckie
- Sarah Kaye, BVSc, is a small animal clinician with the Animal Welfare League Qld Inc. in The Gold Coast, Queensland, Australia. Wenqi Wang, BVSc, PhD, is a postdoctoral fellow affiliated with the School of Veterinary Science at University of Queensland at Gatton in Australia. Craig Miller, DVM, is a postdoctoral fellow in the Department of Microbiology, Immunology & Pathology at Colorado State University in FortCollins, Colorado. Alicia McLuckie, BVSc, is a PhD candidate in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia, Julia A. Beatty, BSc, BVetMed, PhD, FANZCVs (feline med), is a professor in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia. Chris K. Grant, PhD, DSc, is founder and CEO of Custom Monoclonals International Corp. in West Sacramento, California. Sue VandeWoude, DVM, MS, DACLAM, is a professor in the Department of Microbiology, Immunology & Pathology at Colorado State University and Associate Dean for Research in the College of Veterinary & Biomedical Sciences at Colorado State University in Fort Collins, Colorado. Helle Bielefeldt-Ohmann, DVM, PhD, is a senior lecturer in the School of Veterinary Science at the University of Queensland at Gatton, an affiliate senior lecturer in the School of Chemistry & Molecular Biosciences at the University of Queensland at St. Lucia, and an investigator at the Australian Infectious Diseases Research Centre at the University of Queensland in St. Lucia, Australia
| | - Julia A Beatty
- Sarah Kaye, BVSc, is a small animal clinician with the Animal Welfare League Qld Inc. in The Gold Coast, Queensland, Australia. Wenqi Wang, BVSc, PhD, is a postdoctoral fellow affiliated with the School of Veterinary Science at University of Queensland at Gatton in Australia. Craig Miller, DVM, is a postdoctoral fellow in the Department of Microbiology, Immunology & Pathology at Colorado State University in FortCollins, Colorado. Alicia McLuckie, BVSc, is a PhD candidate in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia, Julia A. Beatty, BSc, BVetMed, PhD, FANZCVs (feline med), is a professor in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia. Chris K. Grant, PhD, DSc, is founder and CEO of Custom Monoclonals International Corp. in West Sacramento, California. Sue VandeWoude, DVM, MS, DACLAM, is a professor in the Department of Microbiology, Immunology & Pathology at Colorado State University and Associate Dean for Research in the College of Veterinary & Biomedical Sciences at Colorado State University in Fort Collins, Colorado. Helle Bielefeldt-Ohmann, DVM, PhD, is a senior lecturer in the School of Veterinary Science at the University of Queensland at Gatton, an affiliate senior lecturer in the School of Chemistry & Molecular Biosciences at the University of Queensland at St. Lucia, and an investigator at the Australian Infectious Diseases Research Centre at the University of Queensland in St. Lucia, Australia
| | - Chris K Grant
- Sarah Kaye, BVSc, is a small animal clinician with the Animal Welfare League Qld Inc. in The Gold Coast, Queensland, Australia. Wenqi Wang, BVSc, PhD, is a postdoctoral fellow affiliated with the School of Veterinary Science at University of Queensland at Gatton in Australia. Craig Miller, DVM, is a postdoctoral fellow in the Department of Microbiology, Immunology & Pathology at Colorado State University in FortCollins, Colorado. Alicia McLuckie, BVSc, is a PhD candidate in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia, Julia A. Beatty, BSc, BVetMed, PhD, FANZCVs (feline med), is a professor in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia. Chris K. Grant, PhD, DSc, is founder and CEO of Custom Monoclonals International Corp. in West Sacramento, California. Sue VandeWoude, DVM, MS, DACLAM, is a professor in the Department of Microbiology, Immunology & Pathology at Colorado State University and Associate Dean for Research in the College of Veterinary & Biomedical Sciences at Colorado State University in Fort Collins, Colorado. Helle Bielefeldt-Ohmann, DVM, PhD, is a senior lecturer in the School of Veterinary Science at the University of Queensland at Gatton, an affiliate senior lecturer in the School of Chemistry & Molecular Biosciences at the University of Queensland at St. Lucia, and an investigator at the Australian Infectious Diseases Research Centre at the University of Queensland in St. Lucia, Australia
| | - Sue VandeWoude
- Sarah Kaye, BVSc, is a small animal clinician with the Animal Welfare League Qld Inc. in The Gold Coast, Queensland, Australia. Wenqi Wang, BVSc, PhD, is a postdoctoral fellow affiliated with the School of Veterinary Science at University of Queensland at Gatton in Australia. Craig Miller, DVM, is a postdoctoral fellow in the Department of Microbiology, Immunology & Pathology at Colorado State University in FortCollins, Colorado. Alicia McLuckie, BVSc, is a PhD candidate in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia, Julia A. Beatty, BSc, BVetMed, PhD, FANZCVs (feline med), is a professor in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia. Chris K. Grant, PhD, DSc, is founder and CEO of Custom Monoclonals International Corp. in West Sacramento, California. Sue VandeWoude, DVM, MS, DACLAM, is a professor in the Department of Microbiology, Immunology & Pathology at Colorado State University and Associate Dean for Research in the College of Veterinary & Biomedical Sciences at Colorado State University in Fort Collins, Colorado. Helle Bielefeldt-Ohmann, DVM, PhD, is a senior lecturer in the School of Veterinary Science at the University of Queensland at Gatton, an affiliate senior lecturer in the School of Chemistry & Molecular Biosciences at the University of Queensland at St. Lucia, and an investigator at the Australian Infectious Diseases Research Centre at the University of Queensland in St. Lucia, Australia
| | - Helle Bielefeldt-Ohmann
- Sarah Kaye, BVSc, is a small animal clinician with the Animal Welfare League Qld Inc. in The Gold Coast, Queensland, Australia. Wenqi Wang, BVSc, PhD, is a postdoctoral fellow affiliated with the School of Veterinary Science at University of Queensland at Gatton in Australia. Craig Miller, DVM, is a postdoctoral fellow in the Department of Microbiology, Immunology & Pathology at Colorado State University in FortCollins, Colorado. Alicia McLuckie, BVSc, is a PhD candidate in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia, Julia A. Beatty, BSc, BVetMed, PhD, FANZCVs (feline med), is a professor in the Faculty of Veterinary Science at the University of Sydney in NSW, Australia. Chris K. Grant, PhD, DSc, is founder and CEO of Custom Monoclonals International Corp. in West Sacramento, California. Sue VandeWoude, DVM, MS, DACLAM, is a professor in the Department of Microbiology, Immunology & Pathology at Colorado State University and Associate Dean for Research in the College of Veterinary & Biomedical Sciences at Colorado State University in Fort Collins, Colorado. Helle Bielefeldt-Ohmann, DVM, PhD, is a senior lecturer in the School of Veterinary Science at the University of Queensland at Gatton, an affiliate senior lecturer in the School of Chemistry & Molecular Biosciences at the University of Queensland at St. Lucia, and an investigator at the Australian Infectious Diseases Research Centre at the University of Queensland in St. Lucia, Australia
| |
Collapse
|
3
|
Feline Immunodeficiency Virus Vif N-Terminal Residues Selectively Counteract Feline APOBEC3s. J Virol 2016; 90:10545-10557. [PMID: 27630243 DOI: 10.1128/jvi.01593-16] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2016] [Accepted: 09/10/2016] [Indexed: 01/14/2023] Open
Abstract
Feline immunodeficiency virus (FIV) Vif protein counteracts feline APOBEC3s (FcaA3s) restriction factors by inducing their proteasomal degradation. The functional domains in FIV Vif for interaction with FcaA3s are poorly understood. Here, we have identified several motifs in FIV Vif that are important for selective degradation of different FcaA3s. Cats (Felis catus) express three types of A3s: single-domain A3Z2, single-domain A3Z3, and double-domain A3Z2Z3. We proposed that FIV Vif would selectively interact with the Z2 and the Z3 A3s. Indeed, we identified two N-terminal Vif motifs (12LF13 and 18GG19) that specifically interacted with the FcaA3Z2 protein but not with A3Z3. In contrast, the exclusive degradation of FcaA3Z3 was regulated by a region of three residues (M24, L25, and I27). Only a FIV Vif carrying a combination of mutations from both interaction sites lost the capacity to degrade and counteract FcaA3Z2Z3. However, alterations in the specific A3s interaction sites did not affect the cellular localization of the FIV Vif protein and binding to feline A3s. Pulldown experiments demonstrated that the A3 binding region localized to FIV Vif residues 50 to 80, outside the specific A3 interaction domain. Finally, we found that the Vif sites specific to individual A3s are conserved in several FIV lineages of domestic cat and nondomestic cats, while being absent in the FIV Vif of pumas. Our data support a complex model of multiple Vif-A3 interactions in which the specific region for selective A3 counteraction is discrete from a general A3 binding domain. IMPORTANCE Both human immunodeficiency virus (HIV) and feline immunodeficiency virus (FIV) Vif proteins counteract their host's APOBEC3 restriction factors. However, these two Vif proteins have limited sequence homology. The molecular interaction between FIV Vif and feline APOBEC3s are not well understood. Here, we identified N-terminal FIV Vif sites that regulate the selective interaction of Vif with either feline APOBEC3Z2 or APOBEC3Z3. These specific Vif sites are conserved in several FIV lineages of domestic cat and nondomestic cats, while being absent in FIV Vif from puma. Our findings provide important insights for future experiments describing the FIV Vif interaction with feline APOBEC3s and also indicate that the conserved feline APOBEC3s interaction sites of FIV Vif allow FIV transmissions in Felidae.
Collapse
|
4
|
Abstract
Nonprimate animal models of HIV-1 infection are prevented by missing cellular cofactors and by antiviral actions of species-specific host defense factors. These blocks are profound in rodents but may be less abundant in certain Carnivora. Here, we enabled productive, spreading replication and passage of HIV-1 in feline cells. Feline fibroblasts, T-cell lines, and primary peripheral blood mononuclear cells supported early and late HIV-1 life cycle phases in a manner equivalent to that of human cells, except that produced virions had low infectivity. Stable expression of feline immunodeficiency virus (FIV) Vif-green fluorescent protein (GFP) in HIV-1 entry receptor-complemented feline (CrFK) cells enabled robust spreading HIV-1 replication. FIV Vif colocalized with feline APOBEC3 (fA3) proteins, targeted them for degradation, and prevented G-->A hypermutation of the HIV-1 cDNA by fA3CH and fA3H. HIV-1 Vif was inactive against fA3s as expected and even paradoxically augmented restriction in some assays. In an interesting contrast, simian immunodeficiency virus SIVmac Vif had substantial anti-fA3 activities, which were complete against fA3CH and partial against fA3H. Moreover, both primate lentiviral Vifs colocalized with fA3s and could be pulled down from cell lysates by fA3CH. HIV-1 molecular clones that encode FIV Vif or SIVmac Vif (HIV-1(VF) and HIV-1(VS)) were then constructed. These viruses replicated productively in HIV-1 receptor-expressing CrFK cells and could be passaged serially to uninfected cells. Thus, with the exception of entry receptors, the cat genome can supply the dependency factors needed by HIV-1, and a main restriction can be countered by vif chimerism. The results raise the possibility that the domestic cat could yield an animal model of HIV-1 infection.
Collapse
|
5
|
Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors. Microbiol Mol Biol Rev 2009; 73:211-32. [PMID: 19487726 DOI: 10.1128/mmbr.00040-08] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
The viral infectivity factor (Vif) is dispensable for human immunodeficiency virus type 1 (HIV-1) replication in so-called permissive cells but is required for replication in nonpermissive cell lines and for pathogenesis. Virions produced in the absence of Vif have an aberrant morphology and an unstable core and are unable to complete reverse transcription. Recent studies demonstrated that human APOBEC-3G (hA3G) and APOBEC-3F (hA3F), which are selectively expressed in nonpermissive cells, possess strong anti-HIV-1 activity and are sufficient to confer a nonpermissive phenotype. Vif induces the degradation of hA3G and hA3F, suggesting that its main function is to counteract these cellular factors. Most studies focused on the hypermutation induced by the cytidine deaminase activity of hA3G and hA3F and on their Vif-induced degradation by the proteasome. However, recent studies suggested that several mechanisms are involved both in the antiviral activity of hA3G and hA3F and in the way Vif counteracts these antiviral factors. Attempts to reconcile the studies involving Vif in virus assembly and stability with these recent findings suggest that hA3G and hA3F partially exert their antiviral activity independently of their catalytic activity by destabilizing the viral core and the reverse transcription complex, possibly by interfering with the assembly and/or maturation of the viral particles. Vif could then counteract hA3G and hA3F by excluding them from the viral assembly intermediates through competition for the viral genomic RNA, by regulating the proteolytic processing of Pr55(Gag), by enhancing the efficiency of the reverse transcription process, and by inhibiting the enzymatic activities of hA3G and hA3F.
Collapse
|
6
|
HIV-1 Vif protein mediates the degradation of APOBEC3G in fission yeast when over-expressed using codon optimization. Virol Sin 2008. [DOI: 10.1007/s12250-008-2957-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
|
7
|
Abstract
Animal models for human immunodeficiency virus (HIV) infection play a key role in understanding the pathogenesis of AIDS and the development of therapeutic agents and vaccines. As the only lentivirus that causes an immunodeficiency resembling that of HIV infection, in its natural host, feline immunodeficiency virus (FIV) has been a unique and powerful model for AIDS research. FIV was first described in 1987 by Niels Pedersen and co-workers as the causative agent for a fatal immunodeficiency syndrome observed in cats housed in a cattery in Petaluma, California. Since this landmark observation, multiple studies have shown that natural and experimental infection of cats with biological isolates of FIV produces an AIDS syndrome very similar in pathogenesis to that observed for human AIDS. FIV infection induces an acute viremia associated with Tcell alterations including depressed CD4 :CD8 T-cell ratios and CD4 T-cell depletion, peripheral lymphadenopathy, and neutropenia. In later stages of FIV infection, the host suffers from chronic persistent infections that are typically self-limiting in an immunocompetent host, as well as opportunistic infections, chronic diarrhea and wasting, blood dyscracias, significant CD4 T-cell depletion, neurologic disorders, and B-cell lymphomas. Importantly, chronic FIV infection induces a progressive lymphoid and CD4 T-cell depletion in the infected cat. The primary mode of natural FIV transmission appears to be blood-borne facilitated by fighting and biting. However, experimental infection through transmucosal routes (rectal and vaginal mucosa and perinatal) have been well documented for specific FIV isolates. Accordingly, FIV disease pathogenesis exhibits striking similarities to that described for HIV-1 infection.
Collapse
|
8
|
Paul TA, Casey JW, Avery RJ, Sutton CA. Expression of feline immunodeficiency virus Vif is associated with reduced viral mutation rates without restoration of replication of vif mutant viruses. Virology 2007; 361:112-22. [PMID: 17169394 DOI: 10.1016/j.virol.2006.11.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2006] [Revised: 09/08/2006] [Accepted: 11/08/2006] [Indexed: 10/23/2022]
Abstract
The vif gene of lentiviruses has been demonstrated to be essential for efficient viral replication in many cell types. Although the Vif protein of feline immunodeficiency virus (FIV) displays limited homology to HIV-1 Vif, the role of vif in FIV replication is not known. We have examined the requirements of vif for replication of a FIV strain isolated from a non-domestic felid, Otocolobus manul (FIV-Oma). In agreement with others, we find that replication of FIV vif mutant molecular clones in CrFK cells is highly attenuated. Initial attempts to rescue vif mutant viruses in trans were limited by lack of detectable wild-type Vif expression from DNA constructs. We demonstrate that FIV-Oma Vif expression can be increased by re-synthesis of the gene to remove splice donor and acceptor sites as well as improving codon usage to a mammalian codon optimized model. Cellular localization of resynthesized Vif (Vif-RS) is cytoplasmic. Clonal stable transfectants expressing HA-tagged Vif-RS do not restore replication levels of vif mutant virus. However, in such cell lines, G-to-A mutation rates in replicating wild-type viruses are reduced.
Collapse
Affiliation(s)
- Thomas A Paul
- Department of Microbiology and Immunology, Cornell University, C4-137 Veterinary Medical Center, Ithaca, NY 14853, USA
| | | | | | | |
Collapse
|
9
|
Barnor JS, Miyano-Kurosaki N, Takaku H, Yamaguchi K, Sakamoto A, Ishikawa K, Yamamoto N, Osei-Kwasi M, Ofori-Adjei D. The middle to 3' end of the HIV-1 vif gene sequence is important for vif biological activity and could be used for antisense oligonucleotide targets. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS 2006; 24:1745-61. [PMID: 16438045 DOI: 10.1080/10810730500265823] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
The human immunodeficiency virus type-1 (HIV-1)-encoded vif protein is essential for viral replication, virion production, and pathogenicity. HIV-1 Vif interacts with the endogenous human APOBEC3G protein (an mRNA editor) in target cells to prevent its encapsidation into virions. Some studies have established targets within the HIV-1 vif gene that are important for its biologic function; however, it is important to determine effective therapeutic targets in vif because of its critical role in HIV-1 infectivity and pathogenicity. The present study demonstrates that virions generated in transfected HeLa-CD4+ cells, especially from HIV-1 vif frame-shift mutant (3' delta vif; 5561-5849), were affected in splicing and had low infectivity in MT-4 cells. In addition, HIV-1 vif antisense RNA fragments constructed within the same region, notably the region spanning nucleic acid positions 5561-5705 (M-3'-AS), which corresponds to amino acid residues 96-144, significantly inhibited HIV-1 replication in MT-4 and reduced the HIV-1 vif mRNA transcripts and reporter gene (EGFP) expression. The generated virions showed low secondary infection in H9 cells. These data therefore suggest that the middle to the 3' end of vif is important for its biological activity in the target cells.
Collapse
Affiliation(s)
- Jacob Samson Barnor
- Department of Life and Environmental Science, Chiba Institute of Technology, Tsudanuma, Narashino, Chiba, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Wichroski MJ, Ichiyama K, Rana TM. Analysis of HIV-1 Viral Infectivity Factor-mediated Proteasome-dependent Depletion of APOBEC3G. J Biol Chem 2005; 280:8387-96. [PMID: 15537645 DOI: 10.1074/jbc.m408048200] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
To study how HIV-1 viral infectivity factor (Vif) mediates proteasome-dependent depletion of host factor APOBEC3G, functional and nonfunctional Vif-APOBEC3G interactions were correlated with subcellular localization. APOBEC3G localized throughout the cytoplasm and co-localized with gamma-tubulin, 20 S proteasome subunit, and ubiquitin at punctate cytoplasmic bodies that can be used to monitor the Vif-APOBEC3G interaction in the cell. Through immunostaining and live imaging, we showed that a substantial fraction of Vif localized to the nucleus, and this localization was impaired by deletion of amino acids 12-23. When co-expressed, Vif exhibited more pronounced localization to the cytoplasm and reduced the total cellular levels of APOBEC3G but rarely co-localized with APOBEC3G at cytoplasmic bodies. On the contrary, Vif(C114S), which is inactive but continues to interact with APOBEC3G, stably associated with APOBEC3G in the cytoplasm, resulting in complete co-localization at cytoplasmic bodies and a dose-dependent exclusion of Vif(C114S) from the nucleus. Following proteasome inhibition, cytoplasmic APOBEC3G levels increased, and both proteins co-accumulated nonspecifically into a vimentin-encaged aggresome. Furthermore in the presence or absence of APOBEC3G, Vif localization was significantly altered by proteasome inhibition, suggesting that aberrant localization may also contribute to the loss of Vif function. Finally mutations at Vif Ile(9) disrupted the ability of Vif or Vif(C114S) to coimmunoprecipitate and to co-localize with APOBEC3G, suggesting that the N terminus of Vif mediates interactions with APOBEC3G. Taken together, these results demonstrate that cytoplasmic Vif-APOBEC3G interactions are required but are not sufficient for Vif to modulate APOBEC3G and can be monitored by co-localization in vivo.
Collapse
Affiliation(s)
- Michael J Wichroski
- Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA
| | | | | |
Collapse
|
11
|
Ribeiro AC, Maia e Silva A, Santa-Marta M, Pombo A, Moniz-Pereira J, Goncalves J, Barahona I. Functional analysis of Vif protein shows less restriction of human immunodeficiency virus type 2 by APOBEC3G. J Virol 2005; 79:823-33. [PMID: 15613310 PMCID: PMC538526 DOI: 10.1128/jvi.79.2.823-833.2005] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2004] [Accepted: 08/27/2004] [Indexed: 11/20/2022] Open
Abstract
Viral infectivity factor (Vif) is one of the human immunodeficiency virus (HIV) accessory proteins and is conserved in the primate lentivirus group. This protein is essential for viral replication in vivo and for productive infection of nonpermissive cells, such as peripheral blood mononuclear cells (PBMC). Vif counteracts an antiretroviral cellular factor in nonpermissive cells named CEM15/APOBEC3G. Although HIV type 1 (HIV-1) Vif protein (Vif1) can be functionally replaced by HIV-2 Vif protein (Vif2), its identity is very small. Most of the functional studies have been carried out with Vif1. Characterization of functional domains of Vif2 may elucidate its function, as well as differences between HIV-1 and HIV-2 infectivity. Our aim was to identify the permissivity of different cell lines for HIV-2 vif-minus viruses. By mutagenesis specific conserved motifs of HIV-2 Vif protein were analyzed, as well as in conserved motifs between Vif1 and Vif2 proteins. Vif2 mutants were examined for their stability, expression, and cellular localization in order to characterize essential domains of Vif2 proteins. Viral replication in various target cells (PBMC and H9, A3.01, U38, and Jurkat cells) and infectivity in single cycle assays in the presence of APOBEC3G were also analyzed. Our results of viral replication show that only PBMC have a nonpermissive phenotype in the absence of Vif2. Moreover, the HIV-1 vif-minus nonpermissive cell line H9 does not show a similar phenotype for vif-negative HIV-2. We also report a limited effect of APOBEC3G in a single-cycle infectivity assay, where only conserved domains between HIV-1 and HIV-2 Vif proteins influence viral infectivity. Taken together, these results allow us to speculate that viral inhibition by APOBEC3G is not the sole and most important determinant of antiviral activity against HIV-2.
Collapse
Affiliation(s)
- Ana Clara Ribeiro
- Instituto Superior de Ciências da Saúde-Sul, Quinta da Granja, Monte da Caparica, 2829-511 Caparica, Portugal
| | | | | | | | | | | | | |
Collapse
|
12
|
Feng F, Davis A, Lake JA, Carr J, Xia W, Burrell C, Li P. Ring finger protein ZIN interacts with human immunodeficiency virus type 1 Vif. J Virol 2004; 78:10574-81. [PMID: 15367624 PMCID: PMC516435 DOI: 10.1128/jvi.78.19.10574-10581.2004] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
Virion infectivity factor (Vif) protein of human immunodeficiency virus type 1 (HIV-1) is essential for the productive infection of primary human CD4 T lymphocytes and macrophages. Vif overcomes the HIV-inhibitory effects of cellular factor APOBEC3G, which has cytidine deaminase activity. We previously reported the isolation of a Vif-interacting ring finger protein, Triad 3, from a human leukocyte cDNA library, using the yeast two-hybrid system. The full-length cellular protein homologue of Triad 3 has been recently identified as the zinc finger protein inhibiting NF-kappaB (ZIN). Sequence analysis indicates that Triad 3 protein contains all four major ring-like motifs of ZIN. We report here that ZIN binds to purified Vif in vitro and that Triad 3/ZIN interacts with HIV-1 Vif in transfected human 293T cells, as demonstrated by coimmunoprecipitation. To test the biological relevance of this interaction, we produced infectious HIV-1 NL4.3 in the presence or absence of cotransfected ZIN. HIV-1 NL4.3 virus stocks produced in the presence of exogenously expressed ZIN were twofold less infectious in a single-cycle infectivity assay than virus produced in the absence of exogenous ZIN. It was further shown that cells infected with HIV NL4.3 virus stocks produced in the presence of exogenously expressed ZIN were impaired in viral DNA synthesis by twofold. The impairment in viral reverse transcription and the reduction in single-cycle viral infectivity were both shown to be dependent on the presence of Vif in the virus producer cells. The possible mechanisms by which ZIN interferes with the early events of HIV-1 replication are discussed.
Collapse
Affiliation(s)
- Feng Feng
- Australian Centre for Hepatitis and HIV Virology Research, Infectious Disease Laboratories, Institute of Medical and Veterinary Science, Frome Rd., Adelaide, Australia 5000
| | | | | | | | | | | | | |
Collapse
|
13
|
Barnor JS, Miyano-Kurosaki N, Yamaguchi K, Sakamoto A, Ishikawa K, Inagaki Y, Yamamoto N, Osei-Kwasi M, Ofori-Adjei D, Takaku H. Intracellular expression of antisense RNA transcripts complementary to the human immunodeficiency virus type-1 vif gene inhibits viral replication in infected T-lymphoblastoid cells. Biochem Biophys Res Commun 2004; 320:544-50. [PMID: 15219863 DOI: 10.1016/j.bbrc.2004.05.201] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2004] [Indexed: 10/26/2022]
Abstract
The human immunodeficiency virus type-1 (HIV-1)-encoded vif protein is essential for viral replication, virion production, and pathogenicity. HIV-1 vif interacts with the endogenous human APOBEC3G protein (an mRNA editor) in target cells to prevent its virions from encapsidation. Although some studies have established targets within the HIV-1 vif gene that are important for its biologic function, it is however important to further screen for effective therapeutic targets in the vif gene that could interfere with the HIV-1 vif-dependent infectivity and pathogenicity. This report demonstrates that HIV-1 vif antisense RNA fragments constructed within mid-3' region, notably the region spanning nucleic acid positions 5561-5705 (M-3'-AS), significantly inhibited HIV-1 replication in MT-4 and H9-infected cells and reduced the HIV-1 vif mRNA transcripts. These data clearly suggest that the above vif fragment, which corresponds to amino acid residues 96-144, could be an effective novel therapeutic target site for gene therapy applications, for the control and management of HIV-1 infection, due to its strong inhibition of HIV-1 replication in cells.
Collapse
Affiliation(s)
- Jacob Samson Barnor
- Department of Life and Environmental Science, 2-17-1 Tsudanuma, 275-0016 Narashino, Chiba, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Cen S, Guo F, Niu M, Saadatmand J, Deflassieux J, Kleiman L. The Interaction between HIV-1 Gag and APOBEC3G. J Biol Chem 2004; 279:33177-84. [PMID: 15159405 DOI: 10.1074/jbc.m402062200] [Citation(s) in RCA: 206] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
APOBEC3G, a member of an RNA/DNA cytidine deaminase superfamily, has been identified as a cellular inhibitor of HIV-1 infectivity, possibly through the dC to dU deamination of the first minus strand cDNA synthesized during reverse transcription. Virions incorporate APOBEC3G during viral assembly in non-permissive cells, and this incorporation is inhibited by the viral protein Vif. The mechanism of APOBEC3G incorporation into HIV-1 is examined in this report. In the absence of Vif, cytoplasmic APOBEC3G becomes membrane-bound in cells expressing HIV-1 Gag, and its incorporation into Gag viral-like particles (VLPs) is proportional to the amount of APOBEC3G expressed in the cell. The expression of Vif, or mutant Gag unable to bind to membrane, prevents the APOBEC3G association with membrane. HIV-1 Gag alone among viral proteins is sufficient for packaging of APOBEC3G into Gag VLPs, and this incorporation requires the presence of Gag nucleocapsid. The presence of amino acids 104-156 in APOBEC3G, located in the linker region between two zinc coordination motifs, is also required for its incorporation into Gag VLPs. Evidence against an RNA bridge facilitating the Gag/APOBEC3G interaction includes data indicating that 1) the incorporation of APOBEC3G occurs independently of viral genomic RNA, 2) a Gag/APOBEC3G complex is immunoprecipitated from cell lysate after RNase treatment, and 3) the zinc coordination motif, rather than the regions flanking this motif, have been implicated in RNA binding in another family member, APOBEC1.
Collapse
Affiliation(s)
- Shan Cen
- Lady Davis Institute for Medical Research and McGill AIDS Centre, Jewish General Hospital, Department of Medicine, McGill University, Montreal, Quebec H3T 1E2, Canada
| | | | | | | | | | | |
Collapse
|
15
|
Liu B, Yu X, Luo K, Yu Y, Yu XF. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J Virol 2004; 78:2072-81. [PMID: 14747572 PMCID: PMC369424 DOI: 10.1128/jvi.78.4.2072-2081.2004] [Citation(s) in RCA: 116] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The Vif protein of human immunodeficiency virus type 1 (HIV-1) is essential for viral evasion of the host antiviral protein APOBEC3G, also known as CEM15. Vif mutant but not wild-type HIV-1 viruses produced in the presence of APOBEC3G have been shown to undergo hypermutations in newly synthesized viral DNA upon infection of target cells, presumably resulting from C-to-U modification during minus-strand viral DNA synthesis. We now report that HIV-1 Vif could induce rapid degradation of human APOBEC3G that was blocked by the proteasome inhibitor MG132. The efficiency of Vif-induced downregulation of APOBEC3G expression depended on the level of Vif expression. A single amino acid substitution in the conserved SLQXLA motif reduced Vif function. Vif proteins from distantly related primate lentiviruses such as SIVagm were unable to suppress the antiviral activity of human APOBEC3G or the packaging of APOBEC3G into HIV-1 Vif mutant virions, due to a lack of interaction with human APOBEC3G. In the presence of the proteasome inhibitor MG132, virion-associated Vif increased dramatically. However, increased virion packaging of Vif did not prevent virion packaging of APOBEC3G when proteasome function was impaired, and the infectivity of these virions was significantly reduced. These results suggest that Vif function is required during virus assembly to remove APOBEC3G from packaging into released virions. Once packaged, virion-associated Vif could not efficiently block the antiviral activity of APOBEC3G.
Collapse
Affiliation(s)
- Bindong Liu
- Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland 21205, USA
| | | | | | | | | |
Collapse
|
16
|
Benedetti CE, Kobarg J, Pertinhez TA, Gatti RM, de Souza ON, Spisni A, Meneghini R. Plasmodium falciparum histidine-rich protein II binds to actin, phosphatidylinositol 4,5-bisphosphate and erythrocyte ghosts in a pH-dependent manner and undergoes coil-to-helix transitions in anionic micelles. Mol Biochem Parasitol 2003; 128:157-66. [PMID: 12742582 DOI: 10.1016/s0166-6851(03)00057-4] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
The recombinant histidine-rich protein II (HRPII) from Plasmodium falciparum was shown to bind actin and phosphatidylinositol 4,5-bisphosphate (PIP(2)) in vitro in a pH-dependent manner, very similar to hisactophilin, an actin-binding protein from ameba. Binding of HRPII to actin and PIP(2) occurred at pH 6.0 and 6.5, but not above pH 7.0. Circular dichroism (CD) spectroscopy confirmed that HRPII interacts with actin at pH below 7.0, as judged by the changes induced in the secondary structure of the HRPII/actin mixture. Further CD analysis demonstrated that HRPII adopts a predominantly alpha-helical conformation with anionic micelles of PIP(2) and SDS, but not with neutral micelles of phosphatidylcholine (PC), a feature that is common to many actin-binding proteins involved in cytoskeleton remodeling. Similarly to hisactophilin, a GFP-HRPII fusion protein shuttled from the cytoplasm to the nucleus of HeLa cells as the cellular pH was lowered from 8.0 to 6.0. HeLa cells transfected with the HRPII gene showed increased levels of histidine-rich proteins (HRPs) in the soluble cell fraction at pH 8.0. At pH 6.0, however, HRPs were detected mainly in the insoluble cell fraction. Interestingly, we found that HRPII binds to human erythrocyte membranes at pH 6.0 and 6.5 but not at pH above 7.0. Our results point to remarkable similarities between HRPII, hisactophilin, and actin-binding proteins. Possible roles of the HRPII during Plasmodium infection are discussed in the light of these findings.
Collapse
Affiliation(s)
- Celso Eduardo Benedetti
- Centro de Biologia Molecular Estrutural (CEBIME), Laboratório Nacional de Luz Sincrotron (LNLS), CP6192, Campinas, SP CEP 13084-971, Brazil.
| | | | | | | | | | | | | |
Collapse
|
17
|
Kao S, Akari H, Khan MA, Dettenhofer M, Yu XF, Strebel K. Human immunodeficiency virus type 1 Vif is efficiently packaged into virions during productive but not chronic infection. J Virol 2003; 77:1131-40. [PMID: 12502829 PMCID: PMC140813 DOI: 10.1128/jvi.77.2.1131-1140.2003] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Packaging of the human immunodeficiency virus type 1 Vif protein into virus particles is mediated through an interaction with viral genomic RNA and results in the association of Vif with the nucleoprotein complex. Despite the specificity of this process, calculations of the amount of Vif packaged have produced vastly different results. Here, we compared the efficiency of packaging of Vif into virions derived from acutely and chronically infected H9 cells. We found that Vif was efficiently packaged into virions from acutely infected cells (60 to 100 copies per virion), while packaging into virions from chronically infected H9 cells was near the limit of detection (four to six copies of Vif per virion). Superinfection by an exogenous Vif-defective virus did not rescue packaging of endogenous Vif expressed in the chronically infected culture. In contrast, exogenous Vif expressed by superinfection of wild-type virus was readily packaged (30 to 40 copies per virion). Biochemical analyses suggest that the differences in the relative packaging efficiencies were not due to gross differences in the steady-state distribution of Vif in chronically or acutely infected cells but are likely due to differences in the relative rates of de novo synthesis of Vif. Despite its low packaging efficiency, endogenously expressed Vif was sufficient to direct the production of viruses with almost wild-type infectivity. The results from our study provide novel insights into the biochemical properties of Vif and offer an explanation for the reported differences regarding Vif packaging.
Collapse
Affiliation(s)
- Sandra Kao
- Laboratory of Molecular Microbiology, Viral Biochemistry Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-0460, USA
| | | | | | | | | | | |
Collapse
|
18
|
Madani N, Millette R, Platt EJ, Marin M, Kozak SL, Bloch DB, Kabat D. Implication of the lymphocyte-specific nuclear body protein Sp140 in an innate response to human immunodeficiency virus type 1. J Virol 2002; 76:11133-8. [PMID: 12368356 PMCID: PMC136615 DOI: 10.1128/jvi.76.21.11133-11138.2002] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
The viral infectivity factor (Vif) of human immunodeficiency virus type 1 (HIV-1) neutralizes an unidentified antiviral pathway that occurs only in nonpermissive (NP) cells. Using a yeast two-hybrid screen of a human lymphocyte cDNA library, we identified several potential Vif partners. One, the nuclear body protein Sp140, was found specifically in all NP cells (n = 12 cell lines tested; P < or = 0.001), and HIV-1 infection induced its partial dispersal from nuclear bodies into cytosolic colocalization with Vif. Our results implicate Sp140 in a response to HIV-1 that may be related to or coordinated with the pathway that inactivates HIV-1 lacking vif.
Collapse
Affiliation(s)
- Navid Madani
- Department of Biochemistry and Molecular Biology, Oregon Health and Science University, Portland, Oregon 97201-3098, USA
| | | | | | | | | | | | | |
Collapse
|
19
|
Chatterji U, de Parseval A, Elder JH. Feline immunodeficiency virus OrfA is distinct from other lentivirus transactivators. J Virol 2002; 76:9624-34. [PMID: 12208941 PMCID: PMC136529 DOI: 10.1128/jvi.76.19.9624-9634.2002] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
The feline immunodeficiency virus (FIV) accessory factor, OrfA, facilitates transactivation of transcription directed by elements of the viral long terminal repeat (LTR). In order to map OrfA domains required for this transactivation, we used N- and C-terminal deletion constructs of the protein, expressed in a Gal4-based transactivation system. The results demonstrated that FIV OrfA, unlike other lentiviral transactivators such as visna virus Tat, is unable to transactivate from minimal promoter-based reporters and requires additional elements of the viral LTR. Stable CrFK-based cell lines were prepared that expressed OrfA to readily detectable levels and in which we were able to demonstrate 32-fold transactivation of an LTR-chloramphenicol acetyltransferase construct. Transactivation was heavily dependent on the presence of an ATF site within the viral LTR. Changing the translation initiation codon context substantially increased the level of production of OrfA from a bicistronic message that also encodes Rev. In the presence of a more favorable context sequence, the upstream expression of OrfA increased 21-fold, with only a 0.5-fold drop in downstream Rev expression. This suggests that Rev translation may occur via an internal ribosomal entry site rather than by leaky scanning.
Collapse
Affiliation(s)
- Udayan Chatterji
- Department of Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA
| | | | | |
Collapse
|
20
|
Affiliation(s)
- C M Steffens
- Department of Microbiology and Immunology, University of Illinois at Chicago, Chicago, Illinois, USA
| | | |
Collapse
|
21
|
Jao DLE, Yu Chen K. Subcellular localization of the hypusine-containing eukaryotic initiation factor 5A by immunofluorescent staining and green fluorescent protein tagging. J Cell Biochem 2002; 86:590-600. [PMID: 12210765 DOI: 10.1002/jcb.10235] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Eukaryotic initiation factor 5A (eIF-5A) is the only protein in nature that contains hypusine, an unusual amino acid residue formed posttranslationally by deoxyhypusine synthase and deoxyhypusine hydroxylase. Although the eIF-5A gene is essential for cell survival and proliferation, the precise function and localization of eIF-5A remain unclear. In this study, we have determined the subcellular distribution of eIF-5A by indirect immunofluorescent staining and by direct visualization of green fluorescent protein tagged eIF-5A (GFP-eIF5A). Immunofluorescent staining of the formaldehyde-fixed cells showed that eIF-5A was present in both the nucleus and cytoplasm. Only the nuclear eIF-5A was resistant to Triton extraction. Direct visualization of GFP tagged eIF-5A in living cells revealed the same whole-cell distribution pattern. However, a fusion of an additional pyruvate kinase (PK) moiety into GFP-eIF-5A precluded the nuclear localization of GFP-PK-eIF-5A fusion protein. Fusion of the GFP-PK tag with three different domains of eIF-5A also failed to reveal any nuclear localization of the fusion proteins, suggesting the absence of receptor-mediated nuclear import. Using interspecies heterokaryon fusion assay, we could detect the nuclear export of GFP-Rev, but not of GFP-eIF-5A. The whole-cell distribution pattern of eIF-5A was recalcitrant to the treatments that included energy depletion, heat shock, and inhibition of transcription, translation, polyamine synthesis, or CRM1-dependent nuclear export. Collectively, our data indicate that eIF-5A gains nuclear entry via passive diffusion, but it does not undergo active nucleocytoplasmic shuttling.
Collapse
Affiliation(s)
- David Li-En Jao
- Department of Chemistry and Chemical Biology, Joint Graduate Program in Cell and Developmental Biology, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854-8087, USA
| | | |
Collapse
|
22
|
Henzler T, Harmache A, Herrmann H, Spring H, Suzan M, Audoly G, Panek T, Bosch V. Fully functional, naturally occurring and C-terminally truncated variant human immunodeficiency virus (HIV) Vif does not bind to HIV Gag but influences intermediate filament structure. J Gen Virol 2001; 82:561-573. [PMID: 11172097 DOI: 10.1099/0022-1317-82-3-561] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
A variant human immunodeficiency virus type 1 (HIV-1) vif gene, vifA45-2, which encodes a protein lacking 19 amino acids at the C terminus but which is fully functional in supporting HIV replication in non-permissive cells has been described previously. By employing newly generated anti-VifA45 serum, further properties of VifA45 and its full-length counterpart, VifA45open, in comparison to Vif from HIV strain BH10 are reported in permissive HeLa and COS-7 cells. The results obtained using confocal microscopic localization studies and in vitro binding assays do not support a requirement for the direct interaction of HIV Gag with Vif. Furthermore and in contrast to previous conclusions, detergent solubility analyses do not demonstrate a role for the C terminus of Vif in mediating localization to the fraction containing cellular membrane proteins. Localization of Vif from HIV strain BH10 to perinuclear aggregates in a small fraction (about 10%) of transfected HeLa cells has been previously reported. The intermediate filament protein vimentin colocalizes to these structures. In contrast, VifA45 and VifA45open form perinuclear aggregates in nearly all transfected HeLa cells; vimentin as well as the cytoskeletal-bridging protein plectin, but not the microtubular protein tubulin, become relocalized to these structures. Interestingly, in COS-7 cells, all of the functional Vif proteins tested (Vif from strain BH10, VifA45 and VifA45open) predominantly localize in the cytoplasm but still induce dramatic aggregation of vimentin and plectin, i.e. in these cells the respective Vif proteins are influencing intermediate filament structure in the absence of colocalization.
Collapse
Affiliation(s)
- Tanja Henzler
- Forschungsschwerpunkt Angewandte Tumorvirologie, F02001, and Forschungsschwerpunkt Krebsentstehung und Differenzierung, A01002, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 242, D-69120 Heidelberg, Germany
| | - Abdallah Harmache
- Forschungsschwerpunkt Angewandte Tumorvirologie, F02001, and Forschungsschwerpunkt Krebsentstehung und Differenzierung, A01002, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 242, D-69120 Heidelberg, Germany
| | - Harald Herrmann
- Forschungsschwerpunkt Angewandte Tumorvirologie, F02001, and Forschungsschwerpunkt Krebsentstehung und Differenzierung, A01002, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 242, D-69120 Heidelberg, Germany
| | - Herbert Spring
- Forschungsschwerpunkt Angewandte Tumorvirologie, F02001, and Forschungsschwerpunkt Krebsentstehung und Differenzierung, A01002, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 242, D-69120 Heidelberg, Germany
| | - Marie Suzan
- Pathogénie des Infections à Lentivirus, INSERM U372, BP178, 13276 Marseille, France3
| | - Gilles Audoly
- Pathogénie des Infections à Lentivirus, INSERM U372, BP178, 13276 Marseille, France3
| | - Therese Panek
- Forschungsschwerpunkt Angewandte Tumorvirologie, F02001, and Forschungsschwerpunkt Krebsentstehung und Differenzierung, A01002, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 242, D-69120 Heidelberg, Germany
| | - Valerie Bosch
- Forschungsschwerpunkt Angewandte Tumorvirologie, F02001, and Forschungsschwerpunkt Krebsentstehung und Differenzierung, A01002, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 242, D-69120 Heidelberg, Germany
| |
Collapse
|
23
|
Dettenhofer M, Cen S, Carlson BA, Kleiman L, Yu XF. Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription. J Virol 2000; 74:8938-45. [PMID: 10982337 PMCID: PMC102089 DOI: 10.1128/jvi.74.19.8938-8945.2000] [Citation(s) in RCA: 91] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
The vif gene of human immunodeficiency virus type 1 (HIV-1) is essential for viral replication, although the functional target of Vif remains elusive. HIV-1 vif mutant virions derived from nonpermissive H9 cells displayed no significant differences in the amount, ratio, or integrity of their protein composition relative to an isogenic wild-type virion. The amounts of the virion-associated viral genomic RNA and tRNA(3)(Lys) were additionally present at normal levels in vif mutant virions. We demonstrate that Vif associates with RNA in vitro as well as with viral genomic RNA in virus-infected cells. A functionally conserved lentivirus Vif motif was found in the double-stranded RNA binding domain of Xenopus laevis, Xlrbpa. The natural intravirion reverse transcriptase products were markedly reduced in vif mutant virions. Moreover, purified vif mutant genomic RNA-primer tRNA complexes displayed severe defects in the initiation of reverse transcription with recombinant reverse transcriptase. These data point to a novel role for Vif in the regulation of efficient reverse transcription through modulation of the virion nucleic acid components.
Collapse
Affiliation(s)
- M Dettenhofer
- Department of Molecular Microbiology and Immunology, Johns Hopkins University School of Hygiene and Public Health, Baltimore, Maryland 21205, USA
| | | | | | | | | |
Collapse
|